Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology firm, announced participation in five virtual investor conferences this May and June 2021. Notable events include Cowen's 2nd Annual Virtual Oncology Innovation Summit on May 21, Jefferies Virtual Healthcare Conference on June 1, Goldman Sachs' Healthcare Conference on June 8, BofA Securities' Napa Biopharma Conference on June 15, and JMP Securities' Life Sciences Conference on June 16. Webcasts will be accessible on their website, where replays will also be available for 30 days.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in five upcoming virtual investor conferences.
Cowen's 2nd Annual Virtual Oncology Innovation Summit
Friday, May 21, 2021
10:20AM PT/1:20PM ET
Jefferies Virtual Healthcare Conference
Tuesday, June 1, 2021
7:00AM PT/10:00AM ET
Goldman Sachs 42nd Annual Global Healthcare Conference
Tuesday, June 8, 2021
8:20AM PT/11:20AM ET
BofA Securities 2021 Napa Biopharma Virtual Conference
Tuesday, June 15, 2021
11:30AM PT/2:30PM ET
JMP Securities Life Sciences Conference
Wednesday, June 16, 2021
8:30AM PT/11:30AM ET
Webcasts will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the SEC, including without limitation in its Form 10-Q for the quarter ended March 31, 2021. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com
FAQ
What investor conferences is Allogene Therapeutics participating in May 2021?
When is Allogene Therapeutics' participation in the Jefferies Virtual Healthcare Conference?
Where can I watch Allogene Therapeutics' investor conference webcasts?
What is Allogene Therapeutics known for?
How long will the conference replays be available for Allogene Therapeutics?
